BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200716
DTEND;VALUE=DATE:20200717
DTSTAMP:20260515T044307
CREATED:20200624T102919Z
LAST-MODIFIED:20200624T102919Z
UID:26023-1594857600-1594943999@www.pharmajournalist.com
SUMMARY:Medical Device Trials
DESCRIPTION:At our first Medical Device Trials virtual event our aim is to support trial sponsors and solution providers internationally to ensure trials are delivered on time\, partnerships are improved and innovations are showcased\, discussing\, deliberating and debating the latest operational and technological challenges with regards to clinical trial in medical devices. Hear talks from Bassil Akra\, Faouzi Kallel from Edwards Lifesciences and many other industry leaders and disrupters!\nURL: https://arena-international.com/ctmd/
URL:https://www.pharmajournalist.com/event/medical-device-trials/
LOCATION:Virtual Event
ORGANIZER;CN="Arena International":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200716
DTEND;VALUE=DATE:20200717
DTSTAMP:20260515T044307
CREATED:20200707T121728Z
LAST-MODIFIED:20200707T122000Z
UID:26229-1594857600-1594943999@www.pharmajournalist.com
SUMMARY:EXCLUSIVE FREE WEBINAR ON Prefilled Syringe Elastomer Components High-quality Solutions for Sensitive Molecules
DESCRIPTION:Join the experts at this free exclusive webinar on the 16th July 2020 at 2pm BST\, hosted by West Pharmaceutical Services\, Inc.We have had over 90 registrations so far\, joining us from:Abbvie\, Aptar\, Aptar Pharma\, BI Pharma GmbH & Co. KG\, BioQ Pharma Inc\, Datwyler\, DEKRA\, Hikma Pharmaceuticals\, j8 Process Consulting Taiwan\, Janssen\, Kansai Plascon\, Lazard\, Lilly\, Nemera\, Novartis\, Ohio State University\, Pfizer Inc\, Regeneron\, Roche\, Sanofi\, Sanofi Pasteur\, Schott\, SCHOTT France\, Sio2 Materials Science\, Softeq\, Sumitomo Rubber North America\, Sun pharma research center\, TUV Italia srl\, TUV Italy\, Vetter Pharma-Fertigung GmbH & Co. KG\, Weiss-Aug Co\, Inc.\, WL Gore\, Zacros (Fujimori Kogyo co. ltd.) and many more!\nWith only less than 2 weeks to go\, if you haven’t already registered your FREE place book your virtual seat here today!Can’t make the date/time? Register your place at the above link and we will send you the webinar\, post event.  \nWebinar OverviewIncreasing demands on quality\, stringent regulations\, trends towards home care treatments by using innovative device technology\, and the development of specialized\, high-value treatments present challenges to companies looking for unique solutions.In this webinar we will cover new elastomer component leading with innovation excellence developed to address the ever-increasing demands. Additionally\, we discuss the challenges of the pharmaceutical industry driven towards components being essentially free of particulate and meeting customer demand for consistency by assuring dimensional stability.Expert Webinar Hosts from West Pharmaceutical Services\, Inc.Christa Jansen-Otten\,Product Management\, Prefilled Systems & DeliveryWhitney Winters\,Senior Director\, Strategic Marketing and container SystemsFind out more information on the webinar hosts here. \nFor more information on the webinar and to register your free place\,\nplease visit: www.pfs-elastomer-components-webinar.com
URL:https://www.pharmajournalist.com/event/exclusive-free-webinar-on-prefilled-syringe-elastomer-components-high-quality-solutions-for-sensitive-molecules/
LOCATION:Webinar
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200722
DTEND;VALUE=DATE:20200723
DTSTAMP:20260515T044307
CREATED:20200302T091243Z
LAST-MODIFIED:20200514T082403Z
UID:24438-1595376000-1595462399@www.pharmajournalist.com
SUMMARY:Innate Immune Stimulating Therapies Summit – Running Digitally for 2020
DESCRIPTION:Safely Harnessing Novel Targets of the Innate Immune System for Enhanced Anti-Tumor Effects \nThe inaugural Innate Immune Stimulating Therapies Summit is focused on achieving safe and effective clinical and commercial translation of STING and TLR therapies. \n \nJoin the leaders in the field\, from key biotech\, large pharma\, and academia\, to discuss how to optimize the administration of innate immune stimulating therapies from IT delivery through to antibody conjugated approaches. \nIf you are looking to make long lasting connections with industry leaders and take part in discussions about the lessons learned on the journey to translating safe and effective innate immune stimulating therapies for patients in need\, then this is the meeting for you. Join our online community of industry experts here: https://ter.li/52s56v. Earlybird and group discounts apply. Book early to secure the best possible rate on your ticket.
URL:https://www.pharmajournalist.com/event/innate-immune-stimulating-therapies-summit/
LOCATION:Online\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200722
DTEND;VALUE=DATE:20200723
DTSTAMP:20260515T044307
CREATED:20200612T152417Z
LAST-MODIFIED:20200612T155249Z
UID:25917-1595376000-1595462399@www.pharmajournalist.com
SUMMARY:RNAi-Based Therapeutics Summit – Running Digitally for 2020
DESCRIPTION:Digitally Join the RNAi-Based Therapeutics Community \nWe are excited to announce that the RNAi-Based Therapeutics Summit has gone virtual! \nAs the first multi-disciplinary discussion for large pharma\, biotech and academic leaders specifically dedicated to the RNAi therapeutics\, the industry will be coming together on Wednesday\, July 22 to successfully optimize cell-specific strategies\, overcome pharmacology and delivery challenges to accelerate translation and clinical development of RNAi therapeutics in the liver\, CNS and beyond. \nCheck out the official event guide for full speaker and session details. \nJoin this virtual summit to meet those pioneering the field and to hear from 19+ world-class experts that are sharing their latest perspectives: \n\nDong-ki Lee\, Founder & Chief Executive Officer\, OliX Pharmaceuticals\nElena Feinstein\, Chief Scientific Officer\, Quark Pharmaceuticals\nKaryn O’Neil\, Chief Scientific Officer\, Aro Biotherapeutics\nBrooke Rock\, Director\, Amgen\nSharmistha Ghosh\, Associate Director\, Arrowhead Pharmaceuticals\nBaisong Mei\, Senior Global Project Head\, Sanofi\nDavid Corey\, Professor\, UT Southwestern\n\nDownload the updated program to see the full list. \nWith several clinical candidates emerging and momentum building in the field\, join the RNAi-Based Therapeutics Summit – your comprehensive\, industry-focused virtual meeting dedicated to bringing together senior biopharmaceutical leaders from discovery\, translation\, and clinical development functions to advance pioneering RNAi platforms that improve patient outcomes. Secure your ticket now. \nLooking forward to seeing you at our virtual meeting!
URL:https://www.pharmajournalist.com/event/rnai-based-therapeutics-summit-running-digitally-for-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200804
DTEND;VALUE=DATE:20200807
DTSTAMP:20260515T044307
CREATED:20200228T095936Z
LAST-MODIFIED:20200608T092435Z
UID:24358-1596499200-1596758399@www.pharmajournalist.com
SUMMARY:Gene Therapy Immunogenicity
DESCRIPTION:Gene therapies are revolutionizing the therapeutic landscape for rare and inherited diseases. For the field to progress\, however\, there are several unique and complex challenges. Perhaps the most prominent of these challenges is the immune response to gene therapy delivery. \n \nThe inaugural Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better measure\, modulate and predict immune response to your gene therapy candidate. \nUniting industry leaders across the gene therapy space\, this multi-disciplinary forum will enable you to develop more effective and safe gene therapies by discussing how you can: \n\nIdentify and tailor novel capsid proteins for more specific targeting and immunologic evasion\nReduce AAV neutralizing antibodies\nConfidently assess immunosuppression strategies to dampen immune response\n\nAs the only conference dedicated to the immunogenicity of gene therapies\, this will be an unrivalled opportunity to join 80+ like-minded thought-leaders from cross-disciplines to foster new connections and partnerships. \nDownload the full event guide to learn more from companies including BioMarin\, Spark Therapeutics and Novartis.
URL:https://www.pharmajournalist.com/event/gene-therapy-immunogenicity/
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200812
DTEND;VALUE=DATE:20200813
DTSTAMP:20260515T044307
CREATED:20200624T103810Z
LAST-MODIFIED:20200624T103810Z
UID:26029-1597190400-1597276799@www.pharmajournalist.com
SUMMARY:Vaccines Virtual Conference
DESCRIPTION:Due to the current climate\, we have taken the initiative to launch our very first vaccines conference! Join industry experts from across the globe\, conversing in the latest innovations in COVID-19 and other leading vaccine studies. Brought directly to your home –  listen to leading organisations such as GlaxoSmithKline\, Sanofi\, Pfizer along with leading biotech’s and is completely FREE! Featuring sessions COVID-19 Vaccine Updates\, overcoming manufacturing challenges within the industry \, managing clinical trials during a pandemic\, consideration needed in commercialising your vaccine and more\, this event is crucial to ensure you are up to date with the latest developments in the vaccine space. \n\nURL: https://arena-international.com/vaccine-virtual/
URL:https://www.pharmajournalist.com/event/vaccines-virtual-conference/
LOCATION:Virtual Event
ORGANIZER;CN="Arena International":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200818
DTEND;VALUE=DATE:20200819
DTSTAMP:20260515T044307
CREATED:20200630T114013Z
LAST-MODIFIED:20200630T114013Z
UID:26126-1597708800-1597795199@www.pharmajournalist.com
SUMMARY:Hemophilia Drug Development Summit – Running Digitally for 2020
DESCRIPTION:With the recent Hemlibra approval and the gene therapy revolution\, we are seeing a much-needed race to innovate more effective\, long-lasting and curative therapies for hemophilia and acquired bleeding disorders. \nAs such\, the 3rd Hemophilia Drug Development Summit is going digital and remains dedicated to bringing to patients more effective commercially and clinically translated therapies from small molecules to gene therapies to improve patients’ quality of life. \n \nBringing together over 100 of the world’s leading experts and drug developers\, we discuss how to develop new therapies for a responsive subset of hemophiliac patients\, optimize clinical trial development (setup and management) and discuss the patient/payer paradigm to ensure these novel therapies are affordable and accessible. \nBrought direct to your home office with a jam packed agenda and online virtual networking opportunities\, this exclusive virtual summit will delve into the challenges of treating each patient subset\, as well as hearing the latest advancements in gene therapy and discussing the critical hurdles that need to be overcome to meet the unmet clinical need of all patients. \nJoin us as we unite drug developers and researchers on a dedicated online platform and look to the innovation driving the field towards more long-acting and curative therapies to improve patient quality of life. \nTo know more about Hemophilia Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/hemophilia-drug-development-summit-running-digitally-for-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200827
DTEND;VALUE=DATE:20200828
DTSTAMP:20260515T044307
CREATED:20200716T135808Z
LAST-MODIFIED:20200716T135808Z
UID:26353-1598486400-1598572799@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200831
DTEND;VALUE=DATE:20200903
DTSTAMP:20260515T044307
CREATED:20200703T082824Z
LAST-MODIFIED:20200703T082824Z
UID:26146-1598832000-1599091199@www.pharmajournalist.com
SUMMARY:Blood-Brain Barrier (BBB) Summit
DESCRIPTION:Going digital in its 2nd year\, the Blood-Brain Barrier (BBB) Summit is the industry’s definitive BBB conference focused on sharing the latest scientific advances\, data and key lessons learned for transporting more drugs across the BBB. \nWith a heavy focus on biologics\, for neurodegenerative diseases\, this summit will discuss topics such as quantitative methodologies for measuring amount and distribution of antibodies in the brain\, using PKPD systems to improve translation and predict clinical outcomes and importantly\, progress in the validation of approaches and technologies which enhance BBB transition. \nMoreover\, this meeting also aims to deepen your understanding of intracellular trafficking and receptor binding\, pharmacokinetics and protein engineering to drive the clinical applicability of receptor mediated transcytosis. The 2nd BBB Summit delves into identifying gaps in the physiology of the BBB and questions the extent of the relationship between the BBB and different disease states in various neurodegenerative diseases as well as uncovering what makes neural exosomes efficient BBB drug delivery tools. \nJoin fellow BBB specialists virtually to scrutinize progress of existing approaches to deliver more of your biologic therapeutic across the BBB to develop a clinically defining neurodegenerative treatment. \nTake a look at the full event guide here.
URL:https://www.pharmajournalist.com/event/blood-brain-barrier-bbb-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200903
DTEND;VALUE=DATE:20200905
DTSTAMP:20260515T044307
CREATED:20190926T131642Z
LAST-MODIFIED:20200317T131504Z
UID:22566-1599091200-1599263999@www.pharmajournalist.com
SUMMARY:ProcureCon Pharma 2020
DESCRIPTION:Taking place on 3 – 4 September 2020 in Berlin\, ProcureCon Pharma is your only opportunity to benchmark with the leaders of pharma procurement. \nJoin 120+ senior procurement professionals from Merck\, Astra Zeneca\, Roche\, Sanofi\, Lonza and other world leading Pharma businesses over 2 days and 40 interactive sessions that will help you make better outsourcing decisions\, speed up transformation\, co-create value with business partners and unlock more innovation from suppliers. To learn more about ProcureCon Pharma\, download the agenda. \nTake away answers to all of your top challenges: \n\nDeliver on and communicate value-added procurement activities to increase credibility as a business partner\nIdentify and adopt eProcurement technologies to modernize procurement\nMove from buyers and sellers to long-term strategic partners through SRM and Supplier-Led Innovation\n\nFor more information including the incredible speaker line-up\, download the agenda here:  http://bit.ly/2mnKKSw \nBook your place online today: http://bit.ly/2kR13a2  and get 15% off the current ticket price with our exclusive discount code – “PJOURNALIST20”
URL:https://www.pharmajournalist.com/event/procurecon-pharma-2020/
LOCATION:HOTEL PALACE BERLIN\, Germany
ORGANIZER;CN="Worldwide Business Research":MAILTO:ellie.boynett@wbr.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200908
DTEND;VALUE=DATE:20200909
DTSTAMP:20260515T044307
CREATED:20200908T095405Z
LAST-MODIFIED:20200908T095405Z
UID:26947-1599523200-1599609599@www.pharmajournalist.com
SUMMARY:Glioblastoma Drug Development Summit
DESCRIPTION:After an exceptionally successful inaugural launch last year\, the 2nd Annual Glioblastoma Drug Development Summit returns this year in an exclusive virtual format. \nGBM Drug Development is the only devoted meeting for large pharma\, biotech and pioneering academics which guarantees to unite all stakeholders under a mutual and ambitious objective of accelerating the practical discovery\, translation\, and clinical development of safe\, effective and deliverable therapies to treat glioblastoma\, an extremely aggressive cancer with a huge medical unmet need. \n \nConfronting specific and applied drug development obstacles with inadequate successful treatments\, such as the knowledge of glioblastoma’s mechanisms of resistance and lack of penetration via the blood brain barrier\, the 2nd Glioblastoma Drug Development Summit will help neuro-oncologists\, neurosurgeons  and oncology professionals from biopharma effectively translate their drug candidates into human clinical trials\, whilst optimizing the clinical development process itself to evade further clinical failures. \n\nBrought direct to your home office with a jam-packed agenda and online virtual networking opportunities\, this exclusive virtual summit will delve into the common challenges with developing GBM therapies\, whilst striving to advance safe and effective therapeutic breakthroughs to patients in need. \n\nTo know more about Glioblastoma Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/glioblastoma-drug-development-summit/
LOCATION:Online
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200916
DTSTAMP:20260515T044307
CREATED:20200415T103418Z
LAST-MODIFIED:20200724T145350Z
UID:25038-1600041600-1600214399@www.pharmajournalist.com
SUMMARY:Pre-filled Syringes San Francisco
DESCRIPTION:SMi is proud to announce the inaugural Prefilled Syringes San Francisco event taking place in September 2020. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation\, new digital technology trends\, human studies and innovative design and delivery systems within the prefilled syringe industry. \n \nAs part of SMi’s leading Injectable conference series\, we will assess digital health and connected devices\, biologics\, biosimilars and biocompatibility for drug device combination products\, platform and device selection\, regulatory insights and explore the West Coast’s biotech innovators. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Device Testing Managers\, Senior Device Engineers\, Heads of Device Development\, Heads of Formulation and Drug Process Development\, and many more. \nPlus\, a workshop on human factors and risk management: \n\nIntegration of Human Factors Engineering processes in risk management saves time and money in product development\nEffective identification of use-related risk helps inform constructive design decisions\nMitigation of use-related risk improves treatment outcomes for end users\nUnderstanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization\n\nBenefits of attending: \n\nEXPLORE the latest industry case studies in platform approaches and connected devices\nGAIN insights from leading industry and regulatory experts on the pre-filled syringes environment\nHEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space\nENGAGE in the key challenges and topics of the field in two interactive half-day workshops\n\nChairs for 2020: \n\nShannon Clark\, Principal\, UserWise\nSteven Badelt\, Founder and Managing Partner\, Suttons Creek\, Inc.\n\nFeatured 2020 speakers include: \n\nKristina Lauritsen\, Combination Products Regulatory Advisor\, FDA/CDER\nManuela Gazzard\, Group Executive Director Regulatory Services Healthcare\, BSI\nChristine Lynn Lanning\, Distinguished Scientist\, Device Area Leader\, Safety Assessment/Merck & Co.\, Inc\nKhaudeja Bano\, Senior Medical Director\, Abbott Laboratories\nJace Blackburn\, Smart Device Engineer\, Genentech\nMichael Koby\, Senior Principle Scientist\, Pfi zer\nJames Leamon\, Director of Biologics Device Development\, Jazz Pharmaceuticals\nWalter Goodwin\, Device Engineer\, Device Development & Clinical Packaging Engineering\, Gilead Sciences\nKatie Atkinson\, Manager Human Factors Engineering\, Bigfoot Biomedical\n\n\nEARLY-BIRD RATES: \n\nBOOK BY 30TH APRIL AND SAVE £600\nBOOK BY 29TH MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: #smipfsusa
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-san-francisco/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200916
DTSTAMP:20260515T044307
CREATED:20200415T104121Z
LAST-MODIFIED:20200416T132625Z
UID:25043-1600041600-1600214399@www.pharmajournalist.com
SUMMARY:Future Pharma 2020
DESCRIPTION:Future Pharma\nSeptember 14 – 15\, 2020\nBoston Marriott Long Wharf\, Boston\, MA\nwww.pharmaforce.wbresearch.com \n \nFuture Pharma is a two-day event that brings together heads of brands and franchises\, marketing\, sales and digital executives from leading pharmaceutical companies in an interactive and energizing setting. It is the only conference designed to help commercial leadership evaluate their personal and non- personal promotions\, align marketing and sales strategies and provide insight on commercial success in a post-pandemic industry landscape. \nWith limited vendor attendance and presentations\, you’ll experience true pharma-to-pharma networking in an interactive format. And by selecting sessions based on the topics you care about most\, you’ll connect with other marketing and sales executives who are focused on having the same\, critical conversations. \nFor more information on Future Pharma 2020\, download the agenda: bit.ly/2Vt69aL \nRegister now and SAVE 25% on your conference pass using our exclusive discount code FP20PJ: https://pharmaforce.wbresearch.com/srspricing
URL:https://www.pharmajournalist.com/event/future-pharma-2020/
LOCATION:Boston Marriott Long Wharf\, 296 State Street\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Worldwide Business Research":MAILTO:futurepharma@wbresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200917
DTSTAMP:20260515T044307
CREATED:20200629T075629Z
LAST-MODIFIED:20200629T075915Z
UID:26114-1600041600-1600300799@www.pharmajournalist.com
SUMMARY:2nd Annual RAS – Targeted Drug Development – Digital Summit
DESCRIPTION:Via the latest data driven case studies from academic and industry pioneers\, the 2nd RAS Targeted Drug Development Summit (running digitally this year!) will shine a spotlight on optimizing the selectivity and tolerability of your anti-RAS therapies\, exploring novel combination strategies and overcome translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come. \n \n\nExplore how to leverage the internal structural biology of RAS mutations in order to produce effective and clinically viable therapies with discussions from E Shaw Research\, The Johns Hopkins University School of Medicine & Hospital for Sick Children\nDeep dive into RAS associated pathways in order to optimize combination therapies with insights from Novartis\, Genentech & Deciphera Oncology\nEvaluate the mechanisms of action and resistance of RAS targets to accelerate target validation and clinical translation with insights fromAbbvie\, PhoreMost & Verastem Oncology\nAdopt novel techniques to successfully target therapeutic vulnerabilities in RAS-driven cancers with lessons learnt from BeiGene\, Genentech\, Revolution Medicines\, Oblique Therapeutics & Aro Biotherapeutics\nExplore the successes and future therapeutic potential of targeting mutation beyond G12C from within the RAS community explored Revolution Medicines\, Francis Crick Institute & MD Anderson Cancer Centre\n\nFollowing the success of RAS-Targeted Drug Discovery Summit in 2019\, we will re-unite the RAS community virtually this coming September with the most comprehensive and definitive conference specifically dedicated to this community. \nJoin 250+ of the leading minds from large pharma\, biotech and academia across the globe who are striving to capitalise on the therapeutic opportunity of targeting RAS through advancing novel mechanisms of action\, improving drug-like properties and accelerating the translation of potent and mutation-targeted 2nd generation RAS targeted therapeutic strategies into human clinical trials.
URL:https://www.pharmajournalist.com/event/2nd-annual-ras-targeted-drug-development-digital-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200915
DTEND;VALUE=DATE:20200919
DTSTAMP:20260515T044307
CREATED:20200818T091000Z
LAST-MODIFIED:20200818T091220Z
UID:26798-1600128000-1600473599@www.pharmajournalist.com
SUMMARY:TIDES: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:The #1 event for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders. Join us for top-notch networking\, high-level industry expert speakers\, innovative company presentations\, interactive scientific poster presentations\, and diverse attendee companies and investors — in a multi-day digital format that you can access from anywhere in the world.
URL:https://www.pharmajournalist.com/event/tides-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200922
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T044307
CREATED:20200615T080459Z
LAST-MODIFIED:20200615T080459Z
UID:25926-1600732800-1600991999@www.pharmajournalist.com
SUMMARY:11th World Bispecific Summit – Running Virtually for 2020
DESCRIPTION:Transforming to a digital platform for the eleventh year\, the World Bispecific Summit will continue to deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational and manufacturing challenges faced in the bispecific field. Whatever your role and interest in the field\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 40+ expert speakers are\, and the topics they will examine\, including how: \n\nMacroGenics are evaluating selection and format optimization of bispecific molecules for a simultaneous blockade of PD-1 and LAG-3 (MGD013) versus PD-1 and CTLA4 (MGD019)\nSound Biologics are pioneering their unique platform\, MabPair Technology for making bi-functional antibody\nInvenra demonstrates preclinical efficacy through the selective elimination of tumor Tregs\nIncyte and Adimab are enhancing the selectivity of bispecific approaches to reduce on-target off-tumor toxicities in solid tumor indications\nGenentech are showcasing how several factors such as epitope\, binding affinity\, format\, target expression\, etc.\, influence the design and development of T-cell bispecific for cancer immunotherapy\n\nDownload the event guide to find out more
URL:https://www.pharmajournalist.com/event/11th-world-bispecific-summit-running-virtually-for-2020/
LOCATION:Virtual Summit
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200924
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T044307
CREATED:20200716T140226Z
LAST-MODIFIED:20200716T140226Z
UID:26355-1600905600-1600991999@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium-1/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200928
DTEND;VALUE=DATE:20200930
DTSTAMP:20260515T044307
CREATED:20200217T113517Z
LAST-MODIFIED:20200817T084802Z
UID:24213-1601251200-1601423999@www.pharmajournalist.com
SUMMARY:2nd European Protein Degradation Congress
DESCRIPTION:With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs\, eyes are focused on how much further protein degradation-based therapeutics will continue to grow within the pharmaceutical industry. \nFollowing huge success in May 2019\, the 2nd European Protein Degradation Congress\, returns on 28th – 29th September 2020\, where you can hear the most up to date and relevant information for the broad range of topics in the field of targeted protein degradation. \n \nNew areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown. \nLeading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway\, providing a clearer picture on what makes a good\, or not good\, target for degradation. \nTo know more about 2nd European Protein Degradation Congress please click here.
URL:https://www.pharmajournalist.com/event/2nd-european-protein-degradation-congress/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201001
DTSTAMP:20260515T044307
CREATED:20200715T141216Z
LAST-MODIFIED:20200715T141216Z
UID:26338-1601424000-1601510399@www.pharmajournalist.com
SUMMARY:Gene Therapy for Inherited Metabolic Disorders
DESCRIPTION:The inaugural Gene Therapy for Inherited Metabolic Disorders Summit will put the spotlight on the understanding of topics from the physiopathology of disease through to the nuances of dosing and delivery methods and designing a trial with endpoints and outcome measures that are meaningful both clinically and to patients. \n \nJoin 60+ industry leaders across the metabolic disorders space to overcome the specific delivery and drug development challenges to accelerate the development of more clinically efficacious\, durable and safe gene therapies for metabolic disorders. \nDon’t miss this opportunity to join pioneers from AstraZeneca\, Amicus Therapeutics and Rocket Pharmaceuticals on this journey to revolutionize the treatment of inherited metabolic disorders. \nTo know more about Gene Therapy for Inherited Metabolic Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-inherited-metabolic-disorders/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201001
DTSTAMP:20260515T044307
CREATED:20200720T141737Z
LAST-MODIFIED:20200720T141737Z
UID:26425-1601424000-1601510399@www.pharmajournalist.com
SUMMARY:Gamma Delta T Therapies Summit
DESCRIPTION:Accelerating the Development of Gamma Delta T Therapies in Oncology \nJoin us on Wednesday\, September 30\, to discuss the precise mechanisms of γδT cells\, examine donor selection for allogeneic therapies\, and deliberate the targeting of solid tumours. \nAs we virtually gather world-leading researchers at the Gamma Delta T Therapies Summit\, learn how the industry is effectively manipulating and engineering gamma delta cells with antibody and cell-based approaches for improved safety\, efficacy and manufacturability to bring to market effective Gamma Delta Therapies for patients in need. \nWith a unique opportunity to pose questions to experts and gain fresh insights on such a fast paced and growing field in a live Q&A\, this digital event is not to be missed. \nFind out more about the event and to see participation opportunities: https://ter.li/qk6gc1
URL:https://www.pharmajournalist.com/event/gamma-delta-t-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200930
DTEND;VALUE=DATE:20201002
DTSTAMP:20260515T044307
CREATED:20200821T150023Z
LAST-MODIFIED:20200821T150023Z
UID:26815-1601424000-1601596799@www.pharmajournalist.com
SUMMARY:5th Annual PREDiCT: 3D Oncology & Tissue Models
DESCRIPTION:The Digital 5th PREDiCT: 3D Oncology & Tissue Models Summit will return this September\, with defined tracks and a fresh speaker line-up\, bringing together preclinical scientists to discuss adoption and commercialization of 3D models as an integral part of drug development study. \nThis event is completely free for Drug Developers\, Researchers and Academics. To register your complimentary pass\, simply follow this link: www.3d-oncology-tissuemodels.com/take-part/register/. \nThis fully online meeting will feature over 30+ senior Preclinical Scientists from oncology to cardiovascular to musculoskeletal and CNS backgrounds\, to share their latest data and lessons learned from clinically translatable 3D models to disease modeling of mechanisms\, to attempting complex multi-cellular/organ systems to boost our understanding of functionality and physiological relevancy. \nEmbark on the 3D trailblazing community to boost your confidence in 3D models and accelerate bench to bedside drug development to provide a truly safe\, and effective treatment for patients! \nAccess your copy of the Full Event Guide here.
URL:https://www.pharmajournalist.com/event/5th-annual-predict-3d-oncology-tissue-models/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201006
DTEND;VALUE=DATE:20201009
DTSTAMP:20260515T044307
CREATED:20200813T124435Z
LAST-MODIFIED:20200813T124843Z
UID:26694-1601942400-1602201599@www.pharmajournalist.com
SUMMARY:The 5th Computational Drug Discovery & Development (CDD) for Biologics Summit
DESCRIPTION:Built with insights from the likes of AbbVie\, Sanofi\, Amgen and Takeda; CDD for Biologics Summit has been specifically designed to help biopharma companies define strategies to further adapt computational tools\, mitigate data availability issues and address computational-experimental challenges to add immediate value to their biologics pipelines. \nThis dedicated platform will enable you to address key challenges such as those of widespread data sharing\, the experimental constraints of generating enough data and the importance of overcoming data silo-ing with organizations\, as well as exploring new opportunities including a novel\, AI-derived approach\, an automated high-throughput engineering platform\, successfully deploying ML algorithms and more. \nAcross 3 days online\, 24 experts will share in-depth their findings on: \n• Leveraging machine learning and computational programs to discover\, design and develop de novo antibodies\n• Model and design structure-based antibody and T cell receptor recognition\n• Computational design of antibodies against spike epitopes of SARS-CoV-2\n• Plug and play application and advantages of computational design\n• Deep dives into computational modeling of immunogenicity prediction\, validation; and opportunities for data availability and sharing \nJoin a diverse faculty of experts this October for the 5th annual gathering to uncover progress made\, and how we can accelerate the adoption of computational tools in the discovery and development of biologics. \nTo know more about CDD for Biologics Summit please click here.
URL:https://www.pharmajournalist.com/event/the-5th-computational-drug-discovery-development-cdd-for-biologics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201007
DTEND;VALUE=DATE:20201008
DTSTAMP:20260515T044307
CREATED:20200903T084056Z
LAST-MODIFIED:20200903T084056Z
UID:26934-1602028800-1602115199@www.pharmajournalist.com
SUMMARY:Pulsed x-ray technology & smart optics for a total inspection of pre-fillable syringe cannulas and needle shields
DESCRIPTION:HOSTED BY: HEUFT \nLED BY: DAN MCKEE\nGeneral Manager\, HEUFT USA Inc \nDan McKee is the General Manager of HEUFT USA. He has spent 25 years working with high-speed quality control inspection equipment in the packaging industry. In doing so\, he’s become well versed in non-destructive techniques for testing a wide variety of package attributes using technologies as diverse as x-ray imaging\, capacitive gauging\, inductive profiling\, and various vision techniques. His responsibilities have included commissioning inspection devices within a wide variety of production environments\, specifying devices to satisfy customers’ application conditions and working with R&D to customize equipment to conform to his customers’ unique challenges. Dan now leads HEUFT’s sales and service organization for the United States and Canada. \nDan Received his BSEE from the Illinois Institute of Technology in 1993\, and a Master of Engineering Management (MEM) in 2001 from Northwestern University. \n \nLED BY: RONALD TURN\nPharmaceutical Sales Engineer\, HEUFT USA Inc \nRonald Turn joined Heuft USA in 2019 as the Pharmaceutical Sales Representative. Ron has spent the past 10 years in a technical sales roll selling different varieties of Capital Analytical Research Instrumentation to the Pharmaceutical\, Biotech\, Chemistry\, and Life Sciences industries. Ron also has worked for two major Pharmaceutical companies as an Analytical Chemist. With the combination of sales experience and Scientific knowledge\, Ron is responsible for everything related to the Pharmaceutical portfolio offered by Heuft USA. \nRon Received his bachelor’s degree in Chemistry from Western Illinois University in 2008. \nWebniar overview: \nThe pulsed X-ray detection module from HEUFT identifies numerous safety and integrity defects of pre-fillable syringes after the caps have been applied with unrivaled low radiation. The HEUFT Syringer detects non-conformities that would normally be invisible to a camera system such as needle shields (both SNS & RNS) pierced by the hypodermic needle\, deformed cannulas or incorrectly assembled\, defective or leaking luer-lock screw adapters and tamper evident closures of disposable syringes. \nThe compact detection unit can be enhanced with innovative smart optics for detecting needle hooks which complement the unique pulsed X-ray technology for a careful and precise pre-fillable syringe inspection. An intelligent color sensor camera\, developed by HEUFT\, examines the tiny needle tips from above before the protective covers have been added. The special light dispersion of the adaptive LED lighting used for this purpose ensures that even the smallest faults become visible. \nThe HEUFT Syringer is extremely compact and very easy to integrate into packaging machines for such pre-fillable injection instruments.\nDuring this Webinar\, Information will be shared about the Heuft Syringer such as design features\, functionality\, implementation\, and benefits of using the HEUFT Syringer to assure only quality pre-filled syringes reach the market. \nWHO SHOULD ATTEND?  \n\nQuality Managers\nHeads of Quality\nManufacturing/Operations Managers\nHeads of Manufacturing/Operations\nHeads of Fill-Finish\nFill-Finish Manager\nR&D scientists\nFormulation scientists\nCMC regulatory\nPackaging engineers\nEngineers and Managers in Device Development and all other technical functions surrounding syringe systems\nClinical and commercial Drug Product Manufacturing\nFormulation scientists\nLaboratory scientific staff and managers\nParenteral manufacturing staff\nSterility Quality Assurance\nRegulatory affairs scientists\nPharmaceutical packaging component manufacturing staff\n\nFor more information and to register your free place\, visit:\nhttps://www.smi-online.co.uk/pharmaceuticals/webinar/pfs-cannulas-and-shields \nAdditional Contact Information \nJinna Sidhu – Marketing Manager\nPharmaceutical Division – SMi Group Ltd\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/pulsed-x-ray-technology-smart-optics-for-a-total-inspection-of-pre-fillable-syringe-cannulas-and-needle-shields/
LOCATION:Virtual Webinar
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260515T044307
CREATED:20200422T100729Z
LAST-MODIFIED:20200422T100729Z
UID:25164-1602115200-1602287999@www.pharmajournalist.com
SUMMARY:2nd Flow Cytometry Congress
DESCRIPTION:As a vital tool for providing quantifiable data on cell characteristics\, flow cytometry is an integral part of diagnostics and the assessment of therapeutic efficacy. Talks will also explore the application of flow cytometry in disease monitoring and diagnosis\, and approaches to implementation in the clinic. \n \nThe meeting will focus on: \n\nAdvances in flow cell and sheath fluid design.\nThe development of new fluorophores.\nNext-generation detection systems\, and\nAn applications session exploring the analysis of cell surface antigens\, reviewing cell health\, cell sorting techniques and\nThe role of flow cytometry in drug development.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field. \nDelegates will also have access to the co-located Liquid Biopsies Congress and qPCR and Digital PCR Congress. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/2nd-flow-cytometry-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260515T044307
CREATED:20200422T101205Z
LAST-MODIFIED:20200422T101205Z
UID:25169-1602115200-1602287999@www.pharmajournalist.com
SUMMARY:7th QPCR & Digital PCR Congress
DESCRIPTION:qPCR & Digital PCR are the most essential techniques used for quantification of nucleic acid molecules in molecular biology and diagnostics. \nWhere qPCR is considered as a powerful technique that can provide precise and quantitative data reflecting the biology of the tested experimental parameters\, the excellent precision of dPCR supports its application for the detection of rare point mutations and mutations induced by gene editing in a background of wild-type sequences. \n \nAt this congress our expert speaker panel will address these challenges in the form of case studies and interactive sessions. The agenda will focus on the challenges which need to be addressed to successful move forward into clinical studies: \n\nAccuracy\nReproducibility\nAssay optimization\nMultiplexing\nStandardization\nTranslating methods into applications\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field. \nDelegates will also have access to the co-located Flow Cytometry Congress and Liquid Biopsies Congress. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-qpcr-digital-pcr-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260515T044307
CREATED:20200422T101655Z
LAST-MODIFIED:20200422T101655Z
UID:25174-1602115200-1602287999@www.pharmajournalist.com
SUMMARY:2nd Liquid Biopsies Congress
DESCRIPTION:This conference offers experts working in the biopharmaceutical industry as well as academia the opportunity to examine the latest developments in the field with dedicated congress presentations\, panel discussions and roundtables. \n \nThe agenda will explore : \n\nNovel methods\, research techniques\, advances and discoveries in the field.\nResearch applications utilizing technologies such as qPCR\, Digital PCR and NGS.\nThe detection and analysis of on circulating biomarkers such as cell-free DNA\, (cfDNA)\, circulation tumor cells (CTCs)\, and extracellular vesicles (EVs).\nThe growing field of single cell analysis and he use of different fluids for non-invasive testing.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field. \nDelegates will also have access to the co-located Flow Cytometry Congress and qPCR & Digital PCR Congress. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/2nd-liquid-biopsies-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201012
DTEND;VALUE=DATE:20201014
DTSTAMP:20260515T044307
CREATED:20200213T113228Z
LAST-MODIFIED:20200415T082610Z
UID:24131-1602460800-1602633599@www.pharmajournalist.com
SUMMARY:Animal Health Investment USA
DESCRIPTION:Animal Health Investment USA is a premier investment forum showcasing the most exciting partner opportunities in animal health and connecting those businesses together with financial investors and strategic corporate partners. \n \nOnce again\, our forum in Boston will be split into two tracks\, a human biotech and animal health partnering track and an investor track. The first will be looking specifically at maximizing the therapeutic and commercial potential of human technologies and serving unmet medical needs in veterinary health\, the second will be focused on driving investor engagement and showcasing the industry’s most exciting emerging companies. \nWe will include keynote presentations and host C-level panel discussions that address the trends and market dynamics of the animal health industry\, across all species. A key element of the investment forum is the full use of a our 1-on-1 meeting scheduler\, available to all attendees. \nTo know more about Animal Health Investment USA please click here.
URL:https://www.pharmajournalist.com/event/animal-health-investment-usa/
LOCATION:Venue tbc\, Boston\, MA\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201013
DTEND;VALUE=DATE:20201016
DTSTAMP:20260515T044307
CREATED:20200803T085442Z
LAST-MODIFIED:20200803T085442Z
UID:26601-1602547200-1602806399@www.pharmajournalist.com
SUMMARY:3rd Targeted Protein Degradation Summit
DESCRIPTION:Off the back of the newly released first-in-human data utilizing PROTACs\, it is more than ever evident that the field of targeted protein degradation is redefining the therapeutic landscape across the whole of the pharmaceutical industry. Despite the recent success\, significant challenges are continuing to hold back the progress of the discovery and development of safe and effective protein degraders. \nFor the 3rd time\, the TPD Summit is providing you with the leading platform that showcases the latest developments and advancements in the field\, bringing together the leading biopharmaceutical and academic organizations in an intimate networking environment to focus on successfully degrading intracellular & extracellular targets\, improving rational design and accelerating the translation of next generation proteasomal- & autophagy- mediated protein degraders into clinical trials. \nHere is a sneak peak of just some of our 60+ world-class speaker faculty: \n\nJay Bradner\, President\, Novartis Institutes for Biomedical Research\nCraig Crews\, John C. Malone Professor of MCDB\, Chemistry & Pharmacology\, Yale University\nAlessio Ciulli\, Professor of Chemical & Structural Biology\, University of Dundee\nMatt Disney\, Professor of Chemistry & Neuroscience\, Scripps Research\nIan Churcher\, Chief Scientific Officer\, Amphista Therapeutics\nJohn Houston\, President & Chief Executive Officer\, Arvinas\nRay Deshaies\, Senior Vice President of Global Research\, Amgen\nNello Mainolfi\, Founder\, President & Chief Executive Officer\, Kymera Therapeutics\nStewart Fisher\, Chief Scientific Officer\, C4 Therapeutics\nScott Edmondson\, Director & Head of Boston Oncology Chemistry\, AstraZeneca\nYu Shen\, Director of Cancer Biology\, AbbVie\nRichard Glynne\, Chief Scientific Officer\, Lycia Therapeutics\nIngrid Wertz\, Principal Scientist & Project Team Lead\, Genentech\n\nDon’t miss the most comprehensive\, industry-focused meeting in the field specifically dedicated to the discovery and development of targeted protein degradation strategies to advance your pipelines towards success!
URL:https://www.pharmajournalist.com/event/3rd-targeted-protein-degradation-summit/
LOCATION:Digital Event – EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201021
DTSTAMP:20260515T044307
CREATED:20200422T102229Z
LAST-MODIFIED:20200422T102229Z
UID:25178-1603065600-1603238399@www.pharmajournalist.com
SUMMARY:8th Plant Genomics & Gene Editing Congress: USA
DESCRIPTION:The Congress will explore novel strategies and developments in plant genomics and gene editing through a series of case studies and an examination of the latest scientific research. Leaders from academia and industry will consider key developments in gene editing technologies such as CRISPR/Cas9 and TALEN and discuss its application in improving disease resistance\, stress tolerance and crop yield. \n \n\nDiscover how research institutions and agri-biotech are using gene-editing technologies to advance their research.\nLearn how to apply successful bioinformatic strategies to overcome plant phenotyping challenges.\nExplore the impact of gene editing regulation.\nBuilding on existing partnerships and creating new collaborations across industry & academia\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/8th-plant-genomics-gene-editing-congress-usa/
LOCATION:Raleigh-Durham\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201021
DTSTAMP:20260515T044307
CREATED:20200422T102705Z
LAST-MODIFIED:20200422T102705Z
UID:25182-1603065600-1603238399@www.pharmajournalist.com
SUMMARY:5th Partnerships in Biocontrol & Biostimulants Congress: USA
DESCRIPTION:Case studies across the two days will examine developments in biopesticides and biostimulants and the application of new research in increasing crop yield\, improving soil health & nutrient uptake\, and efficient water use. Experts from industry and academia will also discuss pest management strategies and provide regulatory updates in the field. \n \n\nDiscover how research institutions and agri-biotech are developing the next generation of bacterial biostimulants.\nLearn how to apply successful bioinformatic strategies to advance your research.\nExplore the updated understanding of biopesticides and biostimulants regulation.\nHear about insights into the role of plant and soil microbiomes.\nBuild on existing partnerships and create new collaborations across industry & academia.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/5th-partnerships-in-biocontrol-biostimulants-congress-usa/
LOCATION:Raleigh-Durham\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
END:VCALENDAR